The global market for Biomarker Testing Services was estimated at US$700.5 Million in 2024 and is projected to reach US$1.1 Billion by 2030, growing at a CAGR of 8.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Biomarker Testing Services market.
Segments: Service (Biomarker Assay Development & Validation Service, Flow Cytometry Service, Other Services); Type (Molecular Biomarkers, Cellular Biomarkers); End-Use (Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use, CROs End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Biomarker Testing Services Market - Key Trends & Drivers Summarized
Why Is Biomarker Testing Gaining Importance in Modern Healthcare?
Biomarker testing has become a cornerstone of precision medicine, enabling early disease detection, treatment monitoring, and patient stratification for targeted therapies. With the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions, the need for reliable biomarker testing services has surged. These services facilitate more accurate diagnosis and treatment selection, ensuring better patient outcomes and reduced healthcare costs. The increasing reliance on biomarker-based diagnostics is also evident in the rapid expansion of personalized medicine. Pharmaceutical companies are integrating biomarker testing into drug development processes to identify patient populations that would benefit most from specific therapies. Additionally, regulatory agencies are mandating biomarker testing for companion diagnostics, ensuring drug efficacy and safety before market approval. As a result, healthcare providers and diagnostic laboratories are increasingly outsourcing biomarker testing services to specialized laboratories with advanced analytical capabilities.How Are Technological Innovations Enhancing Biomarker Testing Services?
Technological advancements in genomics, proteomics, and bioinformatics are revolutionizing biomarker testing services, making them more precise, cost-effective, and accessible. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques have improved the detection of genetic and molecular biomarkers, allowing for earlier disease identification and risk assessment. Additionally, the integration of artificial intelligence (AI) and machine learning in biomarker data analysis is optimizing test accuracy and accelerating result interpretation. The emergence of liquid biopsy techniques is another groundbreaking development in biomarker testing. These minimally invasive tests enable real-time monitoring of disease progression by analyzing circulating tumor DNA (ctDNA) and other biomarkers in blood samples. Furthermore, advancements in multiplex biomarker assays allow for simultaneous testing of multiple biomarkers, reducing time and costs associated with traditional single-marker tests. As healthcare moves toward data-driven decision-making, these innovations are making biomarker testing services an indispensable tool in modern diagnostics and drug development.What Market Trends Are Driving the Growth of Biomarker Testing Services?
The growing demand for early disease detection and personalized treatment plans is one of the key trends propelling the biomarker testing services market. Healthcare providers and researchers are prioritizing precision diagnostics to tailor treatments to individual patient profiles, leading to increased adoption of biomarker testing across various medical specialties. Oncology remains the largest application area, with biomarker-driven therapies playing a crucial role in immunotherapy, targeted cancer treatments, and chemotherapy response assessment. Another significant trend shaping the market is the rise of decentralized testing models. The shift toward home-based and point-of-care biomarker testing is being fueled by advances in telemedicine and remote patient monitoring technologies. Companies are developing portable biomarker testing kits and wearable biosensors to facilitate real-time health tracking, reducing the need for frequent hospital visits. Moreover, regulatory support for biomarker-driven clinical trials and drug approvals is encouraging pharmaceutical firms to integrate biomarker testing into their development pipelines, further boosting market demand.What Are the Key Growth Drivers for the Biomarker Testing Services Market?
The growth in the Biomarker Testing Services market is driven by several factors including the rising incidence of chronic diseases, increasing adoption of precision medicine, and rapid technological advancements in biomarker detection methods. The expansion of companion diagnostics, which require biomarker testing for drug approval and patient selection, is further fueling market growth. Additionally, the increasing investment in clinical research and biotechnology innovations is expanding the scope of biomarker testing applications. Pharmaceutical companies are leveraging biomarker testing services to streamline drug development, reduce clinical trial failures, and enhance regulatory compliance. The shift toward non-invasive diagnostic techniques, such as liquid biopsy and multiplex biomarker panels, is also accelerating market expansion. As healthcare systems worldwide focus on improving diagnostic accuracy and treatment efficacy, biomarker testing services are expected to experience sustained growth, transforming the future of disease management and precision medicine.Report Scope
The report analyzes the Biomarker Testing Services market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Service (Biomarker Assay Development & Validation Service, Flow Cytometry Service, Other Services); Type (Molecular Biomarkers, Cellular Biomarkers); End-Use (Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use, CROs End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Biomarker Assay Development & Validation Service segment, which is expected to reach US$762.6 Million by 2030 with a CAGR of a 8.3%. The Flow Cytometry Service segment is also set to grow at 7.4% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $184.1 Million in 2024, and China, forecasted to grow at an impressive 7.8% CAGR to reach $178.0 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Biomarker Testing Services Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Biomarker Testing Services Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Biomarker Testing Services Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as ACM Global Laboratories, BioAgilytix Labs, LLC, Biomedica Medizinprodukte GmbH, Charles River Laboratories, Inc., Creative Biolabs and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 22 Featured):
- ACM Global Laboratories
- BioAgilytix Labs, LLC
- Biomedica Medizinprodukte GmbH
- Charles River Laboratories, Inc.
- Creative Biolabs
- Discovery Life Sciences
- Frontage Laboratories, Inc.
- Intertek Group Plc
- Laboratory Corporation of America Holdings
- NorthEast BioLab
- Novigenix SA
- Pacific Biolabs
- Randox Laboratories Ltd.
- Raybiotech, Inc.
- Svar Life Science AB
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ACM Global Laboratories
- BioAgilytix Labs, LLC
- Biomedica Medizinprodukte GmbH
- Charles River Laboratories, Inc.
- Creative Biolabs
- Discovery Life Sciences
- Frontage Laboratories, Inc.
- Intertek Group Plc
- Laboratory Corporation of America Holdings
- NorthEast BioLab
- Novigenix SA
- Pacific Biolabs
- Randox Laboratories Ltd.
- Raybiotech, Inc.
- Svar Life Science AB
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 152 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 700.5 Million |
| Forecasted Market Value ( USD | $ 1100 Million |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
